$CRMD Q4 '24 Earnings Results & Recap
CorMedix reported Q4 2024 EPS of $0.22, exceeding the estimate of $0.13, while revenue of $31.2M also outperformed the estimate of $27.28M; however, net price erosion is expected to begin in Q2 2025 and a major customer delayed implementation, creating uncertainty in the outlook.